Halozyme Therapeutics, Inc. (BMV:HALO)

Market Cap	162.64B +13.4%
Revenue (ttm)	22.80B +31.2%
Net Income	10.92B +51.7%
EPS	86.87 +56.7%
Shares Out	n/a
PE Ratio	14.89
Forward PE	9.81
Dividend	n/a
Ex-Dividend Date	n/a

Volume	350
Average Volume	755
Open	1,395.66
Previous Close	1,381.00
Day's Range	1,395.66 - 1,395.66
52-Week Range	954.15 - 1,395.66
Beta	n/a
RSI	69.90
Earnings Date	Feb 18, 2026

About Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the disper...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1998
• Employees: 350
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: HALO

Financial Performance

In 2024, Halozyme Therapeutics's revenue was $1.02 billion, an increase of 22.44% compared to the previous year's $829.25 million. Earnings were $444.09 million, an increase of 57.71%.

Financial numbers in USD